IL314717A - Crystalline prostacyclin (IP) receptor agonist and uses thereof - Google Patents

Crystalline prostacyclin (IP) receptor agonist and uses thereof

Info

Publication number
IL314717A
IL314717A IL314717A IL31471724A IL314717A IL 314717 A IL314717 A IL 314717A IL 314717 A IL314717 A IL 314717A IL 31471724 A IL31471724 A IL 31471724A IL 314717 A IL314717 A IL 314717A
Authority
IL
Israel
Prior art keywords
prostacyclin
crystalline
receptor agonist
agonist
receptor
Prior art date
Application number
IL314717A
Other languages
English (en)
Hebrew (he)
Original Assignee
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Therapeutics Corp filed Critical United Therapeutics Corp
Publication of IL314717A publication Critical patent/IL314717A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/08—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL314717A 2022-02-15 2023-02-14 Crystalline prostacyclin (IP) receptor agonist and uses thereof IL314717A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263310469P 2022-02-15 2022-02-15
PCT/US2023/013032 WO2023158634A1 (en) 2022-02-15 2023-02-14 Crystalline prostacyclin (ip) receptor agonist and uses thereof

Publications (1)

Publication Number Publication Date
IL314717A true IL314717A (en) 2024-10-01

Family

ID=87578956

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314717A IL314717A (en) 2022-02-15 2023-02-14 Crystalline prostacyclin (IP) receptor agonist and uses thereof

Country Status (9)

Country Link
US (2) US12098116B2 (cg-RX-API-DMAC10.html)
EP (1) EP4479374A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025506098A (cg-RX-API-DMAC10.html)
KR (1) KR20240149924A (cg-RX-API-DMAC10.html)
CN (1) CN118922402A (cg-RX-API-DMAC10.html)
AU (1) AU2023222747A1 (cg-RX-API-DMAC10.html)
CA (1) CA3248736A1 (cg-RX-API-DMAC10.html)
IL (1) IL314717A (cg-RX-API-DMAC10.html)
WO (1) WO2023158634A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023158634A1 (en) 2022-02-15 2023-08-24 United Therapeutics Corporation Crystalline prostacyclin (ip) receptor agonist and uses thereof
IL320516A (en) 2022-10-31 2025-06-01 United Therapeutics Corp Methods for treating pulmonary hypertension
US20250282716A1 (en) 2024-03-11 2025-09-11 United Therapeutics Corporation Methods of making ip-receptor agonists

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2945530A1 (de) 1979-11-10 1981-06-04 Chemische Werke Hüls AG, 4370 Marl Harnstoffe mit cyclischen substituenten, ihre herstellung und verwendung als herbizide
JPH03160438A (ja) 1989-11-20 1991-07-10 Konica Corp ハロゲン化銀カラー写真感光材料
CA2036192A1 (en) 1990-02-13 1991-08-14 Nicholas Meanwell Heterocyclic carboxylic acids and esters
CA2085844A1 (en) 1991-12-27 1993-06-28 Nobuyuki Hamanaka Fused benzeneoxyacetic acid derivatives
JPH06329598A (ja) 1993-05-19 1994-11-29 Daicel Chem Ind Ltd エステルの製造方法
DE4318889A1 (de) 1993-06-07 1994-12-08 Bayer Ag Verfahren zur Herstellung von organischen Carbamaten
CA2185104A1 (en) 1994-03-10 1995-09-14 Kiyoshi Taniguchi Naphthalene derivatives as prostaglandin 12 agonists
JPH11269138A (ja) 1998-03-20 1999-10-05 Mitsubishi Paper Mills Ltd 有機塩基発生剤
US6335459B1 (en) 1998-12-23 2002-01-01 Syntex (U.S.A.) Llc Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators
GB9908934D0 (en) 1999-04-19 1999-06-16 Rolic Ag Liquid crystalline compounds
EP1046631A1 (en) 1999-04-19 2000-10-25 Rolic AG Liquid crystalline compounds
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
JP3938689B2 (ja) 2000-03-16 2007-06-27 エフ.ホフマン−ラ ロシュ アーゲー Ipアンタゴニストとしてのカルボン酸誘導体
WO2002055484A1 (en) 2001-01-12 2002-07-18 Takeda Chemical Industries, Ltd. Biaryl compound, process for producing the same, and agent
TWI316055B (cg-RX-API-DMAC10.html) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
WO2003007888A2 (en) 2001-07-20 2003-01-30 Adipogenix, Inc. Fat accumulation-modulating compounds
MXPA04001253A (es) 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
TWI293715B (en) 2002-10-10 2008-02-21 Sipix Imaging Inc A method for inducing or enhancing the threshold of an electrophoretic display, an electrophoretic fluid and an electrophoretic display
CN1735598A (zh) 2002-11-11 2006-02-15 拜耳医药保健股份公司 作为ip受体拮抗剂的苯基或杂芳基氨基烷烃衍生物
CA2755297A1 (en) 2003-02-10 2004-08-26 Vertex Pharmaceuticals Incorporated Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
GB0317498D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Compounds
KR100806603B1 (ko) 2003-09-22 2008-02-29 에프. 호프만-라 로슈 아게 아미노알킬아미드 치환된 사이클로헥실 유도체
JP4402413B2 (ja) 2003-09-29 2010-01-20 財団法人21あおもり産業総合支援センター U字型化合物およびこれを含む液晶組成物
DE102004006785A1 (de) 2004-02-11 2005-09-08 Mayr, Herbert, Prof. Dr. Verfahren zur CC-Bindungsknüpfung zwischen elektrophilen Substraten und TT-Verbindungen in neutralen bis basischen wässrigen oder alkoholischen Lösungsmitteln ohne den Einsatz einer Lewis- oder Protonensäure
CA2576971A1 (en) 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
JP2006083085A (ja) 2004-09-15 2006-03-30 Kyowa Hakko Kogyo Co Ltd 二環性ピリミジン誘導体の製造法およびその合成中間体
JP4792731B2 (ja) 2004-11-12 2011-10-12 Dic株式会社 重合性液晶組成物及び当該組成物の硬化物
WO2007051255A1 (en) 2005-11-04 2007-05-10 The University Of Sydney Process for the preparation of compounds containing an azacyclic ring system
JP2007161867A (ja) 2005-12-14 2007-06-28 Toyo Ink Mfg Co Ltd インキ組成物
AU2007249827A1 (en) 2006-05-09 2007-11-22 Colorado State University Research Foundation Methods for treating blood disorders
US8895776B2 (en) 2008-03-18 2014-11-25 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
EP2367797A1 (en) 2008-11-26 2011-09-28 Arena Pharmaceuticals, Inc. Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
PT2370413E (pt) 2008-12-08 2015-10-23 Arena Pharm Inc Moduladores do recetor da prostaciclina (pgi2) úteis para o tratamento de distúrbios relacionados com o mesmo
EP2480526A1 (en) 2009-09-23 2012-08-01 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of pgi2 receptor agonists
KR102441249B1 (ko) 2014-10-23 2022-09-08 아레나 파마슈티칼스, 인크. Pgi2 수용체 관련 병태의 치료 방법
IL266518B2 (en) 2016-11-10 2026-05-01 Arena Pharm Inc Methods for treating pulmonary hypertension with combinations of relinfag and other substances
IL268997B2 (en) 2017-03-01 2023-09-01 Arena Pharm Inc Preparations containing pgi2 receptor agonists and processes for their preparation
EP3664792A1 (en) 2017-08-07 2020-06-17 Arena Pharmaceuticals, Inc. Methods of treatment
US12433865B2 (en) 2018-05-16 2025-10-07 Arena Pharmaceuticals, Inc. Compositions comprising PGI2-receptor agonists and processes for the preparation thereof
CN112638865B (zh) * 2018-09-06 2022-07-26 广东东阳光药业有限公司 药物共晶体及其制备方法
WO2023158634A1 (en) 2022-02-15 2023-08-24 United Therapeutics Corporation Crystalline prostacyclin (ip) receptor agonist and uses thereof
CA3245146A1 (en) 2022-03-17 2023-09-21 United Therapeutics Corporation RALINEPAG MEDICATIONS AND THEIR USES

Also Published As

Publication number Publication date
EP4479374A4 (en) 2026-07-01
KR20240149924A (ko) 2024-10-15
US12098116B2 (en) 2024-09-24
JP2025506098A (ja) 2025-03-07
EP4479374A1 (en) 2024-12-25
WO2023158634A1 (en) 2023-08-24
CA3248736A1 (en) 2023-08-24
AU2023222747A1 (en) 2024-08-22
US20240409503A1 (en) 2024-12-12
CN118922402A (zh) 2024-11-08
US20230406815A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
EP4212527A4 (en) GLP-1R RECEPTOR AGONIST COMPOUND AND USE THEREOF
EP4574821B8 (en) Thrb receptor agonist compound and preparation method and use thereof
EP4130005A4 (en) CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF
EP4019524A4 (en) HETEROCYCLIC THR-BETA RECEPTOR AGONIST COMPOUND, PREPARATION METHOD AND USE THEREOF
PL4125881T3 (pl) Nowe zastosowanie agonisty receptora angiotensyny ii typu 2
CA3263797A1 (en) Muscarinic receptor agonists
IL300000A (en) PPAR agonist - crystalline delta
EP4091623A4 (en) CALCIUM SENSING RECEPTOR AGONIST COMPOUND AND ITS APPLICATION
IL305241B1 (en) Carboxylated glucocorticoid receptor agonists
AU2022299608A1 (en) Compositions comprising an agonist of 5-hydroxytryptamine (5-ht) receptor subtype 3
AU2021349680A9 (en) Use of sphingosine-1-phosphate receptor agonist
EP4348428A4 (en) MICROELECTRONIC CIRCUIT WITH DYNAMICALLY ADJUSTABLE COVERAGE FOR IN-SITU TIMING EVENT MONITORS
CA3306882A1 (en) Composition comprising beta-2-adrenergic receptor agonist for transdermal administration
EP4324827A4 (en) PHARMACEUTICALLY ACCEPTABLE SALT OF A SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST AND CRYSTALLINE FORM THEREOF
HK40084786A (en) Gip receptor agonist peptide compounds and uses thereof
HK40108564A (en) Combination of bitter receptor agonist and gut-signaling compound
CA3272753A1 (en) Composition comprising glp-1 receptor agonist and acat inhibitor
HK40116229A (en) Pharmaceutically acceptable salt and crystalline form of glp-1 receptor agonist and preparation method therefor
CA3276371A1 (en) Galanin-2 receptor agonists
HK40048020A (en) Crystalline forms of a farnesoid x receptor agonist
AU2021903786A0 (en) Novel P2X7 receptor antagonists
HK40122612A (en) Glucocorticoid receptor agonists
CA3291371A1 (en) G-protein coupled receptor antagonist
CA3275190A1 (en) Inhalable hormone receptor agonist formulations
GB202401573D0 (en) Video conferencing end-system